No Cover Image

Journal article 735 views 174 downloads

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Stephen C. Bain, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Dungan, Maria C. Faingold, Michael E. Farkouh, Denise R. Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F. Merino-Torres, Michael A. Nauck, Sue D. Pedersen, Wayne H. -H. Sheu, Robert J. Silver, Cees J. Tack, Nikhil Tandon, Ole K. Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain, Steve Bain Orcid Logo

Diabetes, Obesity and Metabolism

Swansea University Author: Steve Bain Orcid Logo

  • 44806.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC-ND).

    Download (856.24KB)

Check full text

DOI (Published version): 10.1111/dom.13553

Published in: Diabetes, Obesity and Metabolism
ISSN: 14628902
Published: 2018
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa44806
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2018-10-09T15:17:39Z
last_indexed 2023-01-11T14:21:35Z
id cronfa44806
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T19:03:29.2067587</datestamp><bib-version>v2</bib-version><id>44806</id><entry>2018-10-09</entry><title>Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2018-10-09</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>14628902</issnPrint><issnElectronic/><keywords/><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2018</publishedYear><publishedDate>2018-12-31</publishedDate><doi>10.1111/dom.13553</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T19:03:29.2067587</lastEdited><Created>2018-10-09T07:14:26.4972423</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Stephen C.</firstname><surname>Bain</surname><order>1</order></author><author><firstname>Ofri</firstname><surname>Mosenzon</surname><order>2</order></author><author><firstname>Rosario</firstname><surname>Arechavaleta</surname><order>3</order></author><author><firstname>Pawel</firstname><surname>Bogda&#x144;ski</surname><order>4</order></author><author><firstname>Abdurrahman</firstname><surname>Comlekci</surname><order>5</order></author><author><firstname>Agostino</firstname><surname>Consoli</surname><order>6</order></author><author><firstname>Chaicharn</firstname><surname>Deerochanawong</surname><order>7</order></author><author><firstname>Kathleen</firstname><surname>Dungan</surname><order>8</order></author><author><firstname>Maria C.</firstname><surname>Faingold</surname><order>9</order></author><author><firstname>Michael E.</firstname><surname>Farkouh</surname><order>10</order></author><author><firstname>Denise R.</firstname><surname>Franco</surname><order>11</order></author><author><firstname>Jeppe</firstname><surname>Gram</surname><order>12</order></author><author><firstname>Cristian</firstname><surname>Guja</surname><order>13</order></author><author><firstname>Pankaj</firstname><surname>Joshi</surname><order>14</order></author><author><firstname>Rachid</firstname><surname>Malek</surname><order>15</order></author><author><firstname>Juan F.</firstname><surname>Merino-Torres</surname><order>16</order></author><author><firstname>Michael A.</firstname><surname>Nauck</surname><order>17</order></author><author><firstname>Sue D.</firstname><surname>Pedersen</surname><order>18</order></author><author><firstname>Wayne H. -H.</firstname><surname>Sheu</surname><order>19</order></author><author><firstname>Robert J.</firstname><surname>Silver</surname><order>20</order></author><author><firstname>Cees J.</firstname><surname>Tack</surname><order>21</order></author><author><firstname>Nikhil</firstname><surname>Tandon</surname><order>22</order></author><author><firstname>Ole K.</firstname><surname>Jeppesen</surname><order>23</order></author><author><firstname>Mette</firstname><surname>Strange</surname><order>24</order></author><author><firstname>Mette</firstname><surname>Thomsen</surname><order>25</order></author><author><firstname>Mansoor</firstname><surname>Husain</surname><order>26</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>27</order></author></authors><documents><document><filename>0044806-29112018161830.pdf</filename><originalFilename>44806.pdf</originalFilename><uploaded>2018-11-29T16:18:30.0930000</uploaded><type>Output</type><contentLength>869437</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><embargoDate>2018-11-28T00:00:00.0000000</embargoDate><documentNotes>Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC-ND).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T19:03:29.2067587 v2 44806 2018-10-09 Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2018-10-09 BMS Journal Article Diabetes, Obesity and Metabolism 14628902 31 12 2018 2018-12-31 10.1111/dom.13553 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T19:03:29.2067587 2018-10-09T07:14:26.4972423 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Stephen C. Bain 1 Ofri Mosenzon 2 Rosario Arechavaleta 3 Pawel Bogdański 4 Abdurrahman Comlekci 5 Agostino Consoli 6 Chaicharn Deerochanawong 7 Kathleen Dungan 8 Maria C. Faingold 9 Michael E. Farkouh 10 Denise R. Franco 11 Jeppe Gram 12 Cristian Guja 13 Pankaj Joshi 14 Rachid Malek 15 Juan F. Merino-Torres 16 Michael A. Nauck 17 Sue D. Pedersen 18 Wayne H. -H. Sheu 19 Robert J. Silver 20 Cees J. Tack 21 Nikhil Tandon 22 Ole K. Jeppesen 23 Mette Strange 24 Mette Thomsen 25 Mansoor Husain 26 Steve Bain 0000-0001-8519-4964 27 0044806-29112018161830.pdf 44806.pdf 2018-11-29T16:18:30.0930000 Output 869437 application/pdf Version of Record true 2018-11-28T00:00:00.0000000 Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC-ND). true eng
title Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
spellingShingle Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
Steve Bain
title_short Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
title_full Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
title_fullStr Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
title_full_unstemmed Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
title_sort Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Stephen C. Bain
Ofri Mosenzon
Rosario Arechavaleta
Pawel Bogdański
Abdurrahman Comlekci
Agostino Consoli
Chaicharn Deerochanawong
Kathleen Dungan
Maria C. Faingold
Michael E. Farkouh
Denise R. Franco
Jeppe Gram
Cristian Guja
Pankaj Joshi
Rachid Malek
Juan F. Merino-Torres
Michael A. Nauck
Sue D. Pedersen
Wayne H. -H. Sheu
Robert J. Silver
Cees J. Tack
Nikhil Tandon
Ole K. Jeppesen
Mette Strange
Mette Thomsen
Mansoor Husain
Steve Bain
format Journal article
container_title Diabetes, Obesity and Metabolism
publishDate 2018
institution Swansea University
issn 14628902
doi_str_mv 10.1111/dom.13553
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
published_date 2018-12-31T03:56:14Z
_version_ 1763752829705519104
score 11.013216